L-5-hydroxytryptophan can prevent nociceptive disorders in man.
Prevention of primary pain is a new topic, endowed with social and economic interest. We observed that L-5-HTP can induce a significant decrease of the cropping out of migraine, the commonest primary pain. This finding seems interesting, since it represents the first data in the field and was obtained in a prospective, long-term, placebo controlled study. The result obtained suggests that CNS abnormalities underlying the mechanism of migraine can be changed by L-5-HTP, if the amino acid is administered to subjects who are predisposed to headache.
Nicolodi
M
M
Interuniversity Centre of Neurochemistry, Florence, Italy.
Sicuteri
F
F
D006916:5-Hydroxytryptophan / Q000627:therapeutic use*; D000700:Analgesics / Q000627:therapeutic use*; D001205:Ascorbic Acid / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006930:Hyperalgesia / Q000503:physiopathology*; D008297:Male; D008881:Migraine Disorders / Q000517:prevention & control*; D010146:Pain / Q000517:prevention & control*; D010147:Pain Measurement; D010919:Placebos; D011446:Prospective Studies; D012307:Risk Factors; D013997:Time Factors
D000700:Analgesics; D010919:Placebos; D006916:5-Hydroxytryptophan; D001205:Ascorbic Acid